FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:920-921 March 26, 1998 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Eriksson, B. I.

To the Editor: Eriksson et al. (Nov. 6 issue),¹ in comparing desirudin (Revasc) with enoxaparin (Lovenox) for the prevention of thromboembolic complications after total hip replacement, administered a standard European dosage of enoxaparin (40 mg subcutaneously once daily). In the United States, enoxaparin is approved for this indication at a dosage of 30 mg subcutaneously twice daily. A regimen of 30 mg twice daily is also the current recommendation set forth by the American College of Chest Physicians.²

In the study by Eriksson et al., proximal deep-vein thrombosis was the primary end point. The studies by Colwell et al.³ and . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.